Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma
Leo I. Gordon(Northwestern University), Christine A. White(Queen's University), Brad Pohlman(Cleveland Clinic), Christos Emmanouilides(Interbalkan Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Katie D. Vo(Biogen (United States)), Charles P. Theuer(Halozyme Therapeutics (United States)), Nancy L. Bartlett(Washington University in St. Louis), G. Wiseman(Mayo Clinic), Arturo Molina(Janssen (United States)), Thomas E. Witzig(WinnMed), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Mohamed Darif(Biogen (United States))
Cited by 121
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k